Table 4.
The studies have used nano-platform for the enhancement of ciprofloxacin against different bacteria.
| References | Nanoplatforms for delivery of ciprofloxacin | Bacteria | Outcomes |
|---|---|---|---|
| (180) | Ciprofloxacin-AgNPs |
A. baumannii S. marcescens S. aureus |
Compared to ciprofloxacin alone, this compound showed better antioxidant, anti-biofilm, and antibacterial function against the pathogenic bacteria tested |
| (181) | Chitosan/dysprosium oxide | NA | This nanocomposite has good potential for a controlled drug delivery system |
| (182) | Synthesized red blood cell membrane-coated PLGA | K. pneumoniae | This NP showed good antibacterial and anti-infection ability |
| (183) | Gelatin-sodium carboxymethyl cellulose composite nanogels | S. aureus | This compound showed antibacterial activity with sustained-release performances |
| (184) | Nano-fluid containing carbon nano-tubes | Drug-resistant K. pneumoniae | Simultaneous usage of nano-fluid and antibiotics could enhance antibiotic effectiveness at lower doses |
| (185) | Hemicelluloses from Lallemantia royleana, chitosan/chitin and glutaraldehyde |
S. aureus E. coli |
This compound showed comparable activity against E. coli to that of ciprofloxacin and relatively lower activity in the case of S. aureus |
| (186) | Graphene-silk fibroin macromolecular hydrogel dressings |
S. aureus P. aeruginosa |
This compound improved antibacterial activity against both bacteria and burn wound infection |
| (187) | Clay/alginate/imidazolium-based ionic liquid |
E. coli P. aeruginosa |
Ciprofloxacin-loaded nanocomposites showed significantly higher antibacterial activity in comparison with free ciprofloxacin |
| (188) | Hyaluronic acid functionalized self-nano-emulsifying drug delivery system | Salmonella typhi | The drug-delivery system with ciprofloxacin showed an improved ability to permeate goat intestinal mucus, antibiofilm activity, and oral pharmacokinetics compared to free ciprofloxacin |
| (189) | Ciprofloxacin-azithromycin NPs on chitosan nanocarriers | P. aeruginosa | This compound significantly inhibited the biofilm community of bacteria in comparison to the free ciprofloxacin |
| (190) | Chitosan microspheres/nano hydroxyapatite- titanium | S. aureus | Showed antibacterial activity |
| (191) | Citric acid cross-linked carboxymethyl guar gum nanocomposite films | NA | Enhanced the wound healing |
| (192) | Sodium alginate cross-linked with nano-hydroxyapatite |
P. aeruginosa S. aureus E. coli |
Showed antibacterial, especially against S. aureus |
| (193) | Poly(DL-lactide-co-glycolide) NPs |
P. aeruginosa S. aureus |
The NPs were safer and more effective against bacteria in comparison to free drugs |
| (194) | poly(vinyl alcohol) /citric acid/Ag NPs |
S. aureus E. coli |
Showed an effective antibacterial activity. |
| (195) | Fe3O4@ polyacrylic acid @ZIF-8 |
S. aureus E. coli |
This compound decreased the growth of bacteria |
| (196) | Zn containing mesoporous silica nanospheres into polycaprolactone electrospun fibers | E. coli | Showed antibacterial and wound healing capacity |
| (197) | Cerium-doped nano-bioactive glasses |
P. aeruginosa S. aureus E. coli Bacillus subtilis |
Showed antibacterial activity against all studied bacteria |
| (198) | Nano gold embedded cellulose grafted polyacrylamide nanocomposite hydrogel |
E. coli Shigella flexneri Bacillus cereus Listeria Inuaba |
This nanocomposite with improved rheological and thermal characteristics is suitable and proposed as a good carrier for in vitro release of ciprofloxacin drugs |
NPs, nanoparticles; NA, not applicable; NR, not reported.